| Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co.'s main growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis; movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. Co.'s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We show 48 historical shares outstanding datapoints in our coverage of BIIB's shares outstanding history.|
Understanding the changing numbers of BIIB shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like BIIB versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching BIIB by allowing them to research BIIB shares outstanding history
as well as any other stock in our coverage universe.